This article is more than 5 years old. Information may no longer be current.
Long-acting paliperidone palmitate effective for differing durations of schizophrenia
Click Here to Manage Email Alerts
SAN ANTONIO — Paliperidone palmitate long-acting injectable therapy reduced schizophrenia symptom severity among individuals with differing durations of illness, according to data presented at U.S. Psychiatric and Mental Health Congress.
To assess efficacy of 1-month and 3-month paliperidone palmitate for symptom severity and functional remission among individuals with schizophrenia and differing durations of illness, researchers conducted a post-hoc analysis of a randomized, multicenter, double-blind, parallel-group, noninferiority trial (n = 994). Study participants were randomly assigned to 1-month long-acting injectable paliperidone palmitate therapy or 3-month long-acting injectable paliperidone palmitate for 48 weeks.
Incidence of relapse or all-cause discontinuation did not statistically significantly differ between participants with an illness duration of 5 years or lower, 6 to 10 years or greater than 10 years.
All groups exhibited significantly improved mean change in baseline Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) scores.
Functional remission, indicated by a PSP score greater than 70, was more common among participants with an illness duration of 5 years or lower and 6 to 10 years, compared with those with an illness duration greater than 10 years.
Increased weight was the most common adverse event among all participants.
“These findings provide support for earlier use of 1-month paliperidone palmitate and 3-month paliperidone palmitate in the treatment of schizophrenia to improve symptoms and functional outcomes,” the researchers concluded. – by Amanda Oldt
Reference:
Brown B, et al. Evaluation of paliperidone palmitate long-acting injectable therapy by duration of illness in patients with schizophrenia. Presented at: U.S. Psychiatric and Mental Health Congress; Oct. 21-24, 2016; San Antonio.
Disclosure: The study was supported by Janssen Scientific Affairs, LLC.